| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 52 | 2023 | 164 | 14.800 |
Why?
|
| Anti-Asthmatic Agents | 17 | 2023 | 34 | 5.150 |
Why?
|
| Hypersensitivity | 7 | 2023 | 48 | 2.720 |
Why?
|
| Adrenal Cortex Hormones | 13 | 2023 | 117 | 2.630 |
Why?
|
| Physicians | 6 | 2022 | 121 | 2.620 |
Why?
|
| Telemedicine | 7 | 2023 | 119 | 2.470 |
Why?
|
| Medication Adherence | 12 | 2023 | 81 | 2.320 |
Why?
|
| Patient Education as Topic | 9 | 2021 | 161 | 2.300 |
Why?
|
| Burnout, Professional | 4 | 2022 | 41 | 2.280 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 91 | 1.980 |
Why?
|
| Pneumonia, Viral | 7 | 2020 | 95 | 1.970 |
Why?
|
| Child | 29 | 2023 | 1424 | 1.570 |
Why?
|
| Humans | 79 | 2023 | 28449 | 1.510 |
Why?
|
| Community Health Workers | 7 | 2022 | 35 | 1.400 |
Why?
|
| Administration, Inhalation | 14 | 2022 | 45 | 1.330 |
Why?
|
| Adolescent | 24 | 2023 | 2324 | 1.160 |
Why?
|
| Pandemics | 11 | 2022 | 262 | 1.090 |
Why?
|
| Behavior Therapy | 2 | 2017 | 92 | 1.000 |
Why?
|
| Caregivers | 7 | 2019 | 201 | 0.950 |
Why?
|
| Nebulizers and Vaporizers | 8 | 2022 | 25 | 0.910 |
Why?
|
| Mobile Applications | 2 | 2020 | 32 | 0.820 |
Why?
|
| Betacoronavirus | 5 | 2020 | 77 | 0.800 |
Why?
|
| Emergency Service, Hospital | 8 | 2020 | 257 | 0.790 |
Why?
|
| Biological Products | 1 | 2022 | 45 | 0.750 |
Why?
|
| Environmental Exposure | 2 | 2018 | 14 | 0.710 |
Why?
|
| Allergy and Immunology | 4 | 2020 | 5 | 0.700 |
Why?
|
| Monitoring, Ambulatory | 1 | 2020 | 19 | 0.700 |
Why?
|
| Poverty | 3 | 2020 | 100 | 0.680 |
Why?
|
| Surveys and Questionnaires | 8 | 2022 | 1215 | 0.650 |
Why?
|
| Adult | 20 | 2023 | 8155 | 0.630 |
Why?
|
| Parents | 2 | 2018 | 126 | 0.610 |
Why?
|
| Emigrants and Immigrants | 2 | 2018 | 24 | 0.610 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 7 | 0.600 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 43 | 0.600 |
Why?
|
| Health Literacy | 4 | 2021 | 109 | 0.590 |
Why?
|
| Registries | 1 | 2019 | 190 | 0.590 |
Why?
|
| Female | 31 | 2023 | 15777 | 0.590 |
Why?
|
| Male | 30 | 2023 | 15352 | 0.570 |
Why?
|
| Self Care | 5 | 2020 | 105 | 0.560 |
Why?
|
| Decision Making | 1 | 2018 | 229 | 0.530 |
Why?
|
| Assertiveness | 1 | 2015 | 8 | 0.510 |
Why?
|
| Child, Preschool | 8 | 2022 | 692 | 0.510 |
Why?
|
| Urban Population | 5 | 2013 | 159 | 0.470 |
Why?
|
| Chicago | 7 | 2019 | 912 | 0.460 |
Why?
|
| United States | 9 | 2023 | 2185 | 0.440 |
Why?
|
| Social Support | 2 | 2021 | 216 | 0.430 |
Why?
|
| Family | 3 | 2021 | 113 | 0.420 |
Why?
|
| Bronchodilator Agents | 3 | 2022 | 21 | 0.420 |
Why?
|
| Immunization, Passive | 5 | 2023 | 14 | 0.410 |
Why?
|
| Patient Compliance | 2 | 2011 | 165 | 0.410 |
Why?
|
| MP3-Player | 2 | 2013 | 5 | 0.410 |
Why?
|
| Minority Groups | 4 | 2019 | 87 | 0.400 |
Why?
|
| House Calls | 3 | 2021 | 22 | 0.390 |
Why?
|
| Electronics | 2 | 2021 | 11 | 0.380 |
Why?
|
| Fellowships and Scholarships | 2 | 2022 | 42 | 0.360 |
Why?
|
| Health Services Accessibility | 2 | 2023 | 113 | 0.360 |
Why?
|
| Computer Security | 2 | 2020 | 6 | 0.350 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2020 | 18 | 0.350 |
Why?
|
| Socioeconomic Factors | 5 | 2021 | 312 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2011 | 186 | 0.340 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2021 | 233 | 0.330 |
Why?
|
| Asthma, Exercise-Induced | 1 | 2009 | 1 | 0.320 |
Why?
|
| Hospitalization | 3 | 2022 | 322 | 0.320 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2009 | 16 | 0.320 |
Why?
|
| Athletes | 1 | 2009 | 89 | 0.300 |
Why?
|
| Communication Barriers | 1 | 2007 | 4 | 0.290 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 180 | 0.290 |
Why?
|
| Language | 1 | 2007 | 69 | 0.280 |
Why?
|
| Quality Improvement | 3 | 2018 | 161 | 0.280 |
Why?
|
| Research Design | 2 | 2019 | 208 | 0.270 |
Why?
|
| Electronic Health Records | 3 | 2020 | 75 | 0.240 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 993 | 0.230 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 77 | 0.230 |
Why?
|
| Albuterol | 4 | 2022 | 19 | 0.230 |
Why?
|
| Urticaria | 1 | 2023 | 4 | 0.220 |
Why?
|
| Transfusion Reaction | 1 | 2023 | 7 | 0.220 |
Why?
|
| One Health | 1 | 2023 | 1 | 0.220 |
Why?
|
| Patient Preference | 1 | 2023 | 33 | 0.210 |
Why?
|
| Middle Aged | 8 | 2022 | 9316 | 0.210 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 33 | 0.210 |
Why?
|
| Glucocorticoids | 2 | 2020 | 70 | 0.210 |
Why?
|
| Health Status Disparities | 1 | 2023 | 75 | 0.210 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 3 | 0.200 |
Why?
|
| Adaptive Immunity | 1 | 2022 | 19 | 0.200 |
Why?
|
| Vaccination | 1 | 2022 | 32 | 0.200 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 155 | 0.190 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 54 | 0.190 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 53 | 0.190 |
Why?
|
| Anaphylaxis | 1 | 2021 | 11 | 0.190 |
Why?
|
| Endpoint Determination | 1 | 2021 | 22 | 0.190 |
Why?
|
| Biomedical Technology | 1 | 2021 | 8 | 0.190 |
Why?
|
| Treatment Outcome | 7 | 2022 | 3619 | 0.180 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 940 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 122 | 0.180 |
Why?
|
| Feedback | 1 | 2020 | 32 | 0.180 |
Why?
|
| Remote Sensing Technology | 1 | 2020 | 3 | 0.180 |
Why?
|
| Comparative Effectiveness Research | 2 | 2021 | 6 | 0.180 |
Why?
|
| Clinical Coding | 1 | 2020 | 5 | 0.180 |
Why?
|
| Confidentiality | 1 | 2020 | 7 | 0.180 |
Why?
|
| Self-Management | 2 | 2017 | 14 | 0.180 |
Why?
|
| Mental Health | 2 | 2020 | 123 | 0.180 |
Why?
|
| Tiotropium Bromide | 1 | 2020 | 2 | 0.180 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2020 | 4 | 0.180 |
Why?
|
| Desensitization, Immunologic | 1 | 2020 | 4 | 0.170 |
Why?
|
| Self Report | 1 | 2021 | 226 | 0.170 |
Why?
|
| Depression | 3 | 2020 | 458 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 236 | 0.170 |
Why?
|
| Lung | 1 | 2021 | 169 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 40 | 0.170 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 25 | 0.170 |
Why?
|
| Symptom Flare Up | 1 | 2019 | 2 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2020 | 80 | 0.170 |
Why?
|
| Family Relations | 1 | 2019 | 14 | 0.160 |
Why?
|
| Double-Blind Method | 3 | 2023 | 425 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2020 | 152 | 0.160 |
Why?
|
| Residence Characteristics | 2 | 2019 | 216 | 0.160 |
Why?
|
| Office Visits | 1 | 2019 | 13 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 167 | 0.160 |
Why?
|
| Documentation | 1 | 2019 | 29 | 0.160 |
Why?
|
| Pediatrics | 1 | 2019 | 46 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 82 | 0.150 |
Why?
|
| Outpatients | 3 | 2023 | 59 | 0.150 |
Why?
|
| Occupational Exposure | 1 | 2018 | 18 | 0.150 |
Why?
|
| Patient Participation | 1 | 2018 | 53 | 0.150 |
Why?
|
| Prevalence | 2 | 2018 | 476 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 326 | 0.150 |
Why?
|
| Volunteers | 1 | 2017 | 5 | 0.140 |
Why?
|
| Community Participation | 1 | 2017 | 18 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2017 | 29 | 0.140 |
Why?
|
| Education, Distance | 1 | 2017 | 18 | 0.140 |
Why?
|
| Cell Phone | 1 | 2017 | 7 | 0.140 |
Why?
|
| Risk Factors | 4 | 2021 | 2414 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2016 | 23 | 0.140 |
Why?
|
| Community Mental Health Services | 1 | 2015 | 19 | 0.130 |
Why?
|
| Smartphone | 1 | 2015 | 17 | 0.120 |
Why?
|
| Health Status | 3 | 2021 | 229 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 507 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2022 | 3615 | 0.120 |
Why?
|
| Peer Group | 1 | 2013 | 40 | 0.110 |
Why?
|
| Housing | 1 | 2013 | 19 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2021 | 674 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 184 | 0.100 |
Why?
|
| Animals | 2 | 2023 | 3808 | 0.100 |
Why?
|
| Quality of Life | 3 | 2023 | 663 | 0.100 |
Why?
|
| Obesity | 2 | 2019 | 322 | 0.100 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2012 | 8 | 0.100 |
Why?
|
| Young Adult | 4 | 2022 | 2103 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2017 | 441 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2013 | 443 | 0.100 |
Why?
|
| Aged | 3 | 2022 | 9320 | 0.100 |
Why?
|
| School Health Services | 1 | 2011 | 21 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 68 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 146 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 796 | 0.090 |
Why?
|
| Students | 1 | 2011 | 52 | 0.090 |
Why?
|
| Mexican Americans | 1 | 2011 | 30 | 0.090 |
Why?
|
| Consensus | 2 | 2021 | 98 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2022 | 73 | 0.090 |
Why?
|
| Anti-Allergic Agents | 1 | 2010 | 2 | 0.090 |
Why?
|
| Androstadienes | 1 | 2010 | 7 | 0.090 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2010 | 5 | 0.090 |
Why?
|
| Quinolines | 1 | 2010 | 8 | 0.090 |
Why?
|
| Acetates | 1 | 2010 | 17 | 0.090 |
Why?
|
| Puerto Rico | 3 | 2014 | 13 | 0.080 |
Why?
|
| Anxiety | 2 | 2021 | 160 | 0.080 |
Why?
|
| Allergens | 2 | 2023 | 16 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 36 | 0.080 |
Why?
|
| Disease Progression | 2 | 2022 | 721 | 0.080 |
Why?
|
| Logistic Models | 2 | 2019 | 399 | 0.070 |
Why?
|
| Music | 1 | 2008 | 24 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2021 | 37 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 16 | 0.070 |
Why?
|
| Forced Expiratory Volume | 2 | 2019 | 11 | 0.070 |
Why?
|
| Interleukin-8 | 1 | 2023 | 19 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2023 | 13 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 49 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 1802 | 0.050 |
Why?
|
| Irritants | 1 | 2023 | 1 | 0.050 |
Why?
|
| Community-Based Participatory Research | 2 | 2014 | 43 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 81 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 71 | 0.050 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2023 | 3 | 0.050 |
Why?
|
| Dry Powder Inhalers | 1 | 2022 | 3 | 0.050 |
Why?
|
| Metered Dose Inhalers | 1 | 2022 | 5 | 0.050 |
Why?
|
| Patients | 1 | 2022 | 35 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 43 | 0.050 |
Why?
|
| Cytokines | 1 | 2023 | 236 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 289 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2021 | 45 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2021 | 10 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2022 | 110 | 0.050 |
Why?
|
| Review Literature as Topic | 1 | 2021 | 12 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2021 | 27 | 0.050 |
Why?
|
| Substance-Related Disorders | 2 | 2020 | 96 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 121 | 0.040 |
Why?
|
| London | 1 | 2020 | 2 | 0.040 |
Why?
|
| Terbutaline | 1 | 2020 | 1 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 54 | 0.040 |
Why?
|
| Self Administration | 1 | 2020 | 21 | 0.040 |
Why?
|
| Professionalism | 1 | 2020 | 4 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 6 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 32 | 0.040 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2020 | 8 | 0.040 |
Why?
|
| Guilt | 1 | 2020 | 5 | 0.040 |
Why?
|
| Efficiency | 1 | 2020 | 20 | 0.040 |
Why?
|
| Suicide | 1 | 2020 | 15 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 21 | 0.040 |
Why?
|
| Grief | 1 | 2020 | 19 | 0.040 |
Why?
|
| Community Health Services | 1 | 2020 | 35 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 133 | 0.040 |
Why?
|
| Social Behavior | 1 | 2020 | 72 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 350 | 0.040 |
Why?
|
| Mindfulness | 1 | 2020 | 48 | 0.040 |
Why?
|
| Spirituality | 1 | 2020 | 78 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 110 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 145 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 354 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 87 | 0.040 |
Why?
|
| Social Media | 1 | 2020 | 49 | 0.040 |
Why?
|
| Communication | 1 | 2020 | 124 | 0.040 |
Why?
|
| Curriculum | 1 | 2020 | 150 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 66 | 0.040 |
Why?
|
| Health Promotion | 1 | 2020 | 161 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 181 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 275 | 0.040 |
Why?
|
| Educational Status | 1 | 2019 | 299 | 0.040 |
Why?
|
| Persuasive Communication | 1 | 2017 | 1 | 0.040 |
Why?
|
| Focus Groups | 1 | 2017 | 93 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 502 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2017 | 27 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 1870 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 41 | 0.030 |
Why?
|
| Sinusitis | 1 | 2019 | 162 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 85 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 137 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2016 | 98 | 0.030 |
Why?
|
| Schools | 1 | 2014 | 46 | 0.030 |
Why?
|
| Cotinine | 1 | 2013 | 5 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2013 | 7 | 0.030 |
Why?
|
| Enkephalin, Methionine | 1 | 1993 | 1 | 0.030 |
Why?
|
| Saliva | 1 | 2013 | 60 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 1993 | 49 | 0.030 |
Why?
|
| Vital Signs | 1 | 2012 | 3 | 0.030 |
Why?
|
| Work of Breathing | 1 | 2012 | 6 | 0.030 |
Why?
|
| Spirometry | 1 | 2012 | 12 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 234 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 207 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 135 | 0.020 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 1 | 2010 | 1 | 0.020 |
Why?
|
| Sulfides | 1 | 2010 | 11 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2010 | 15 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2010 | 27 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2012 | 245 | 0.020 |
Why?
|
| Illinois | 1 | 2009 | 247 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 467 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 519 | 0.010 |
Why?
|
| Vietnam | 1 | 1993 | 7 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 169 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 277 | 0.010 |
Why?
|
| Alcoholism | 1 | 1993 | 75 | 0.010 |
Why?
|
| Veterans | 1 | 1993 | 94 | 0.010 |
Why?
|